A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer

Gynecologic Oncology

Volumn 71, Issue 3, 1998, Pages 450-453

  Naumann, R Wendel ^a   Alvarez, Ronald D ^a   Omura, George A ^a   Segars, Ellen ^a   Kilgore, Larry C ^a   Partridge, Edward E ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0032407888     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5205     Document Type: Article

References (22)

1. 1. McGuire WP: Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol Oncol 51:78-85, 1993
2. 2. Thigpen T, Vance R, Puneky L, Khansur T: Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55:S97-S107, 1994
3. 3. de Oliveira CF, Lacave AJ, Villani C, et al.: Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study. Eur J Gynaecol Oncol 11:323-330, 1990
4. 4. Gruppo Interegionale Cooperativo Oncologico Ginecologia: Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Lancet 2:353-359, 1987
5. 5. Bertelsen K, Jakobsen A, Andersen J, et al.: A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 28:161-169, 1987
6. 6. Conte P, Bruzzone M, Chiara S, et al.: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cylophosphamide in advanced ovarian cancer. J Clin Oncol 4:965-1071, 1986
7. 7. Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 9, 1991
8. 8. A'Hern R, Gore M. The impact of doxorubicin on survival in advanced epithelial ovarian cancer. J Clin Oncol 13:726-732, 1994
9. 9. Hill M, Macfarlane V, Moore J, Gore ME. Taxane/platinum/anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol 24:s2-s34, 1997
10. 10. Chan K, Ripley D, Rahaman J, Dottino P, Beddoe A, Cohen C: Combination Taxol, Adriamycin, and cisplatin (TAP) in patients with advanced gynecologic malignancies: preliminary results. Proc Am Soc Clin Oncol 15:294, 1996
11. 11. ten Bokkel Huinink W, Eisenhauer E, Swenerton K. Preliminary evaluation of a multicenter, randomized comparative study of Taxol (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. Cancer Treat Rev 19:79-86, 1993
12. 12. Levi F, Benavides M, Chevelle C, et al.: Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J CHn Oncol 8:705-714, 1990
13. 13. Crawford J, Ozer H, Stoller R, et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
14. 14. Perez E, Hartmann L. Paclitaxel and carboplatin for advanced breast cancer. Semin Oncol 23(suppl 11):41-45, 1996
15. 15. Kemp G, Rose P, Lurain J, et al.: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
16. 16. Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15:2111-2117, 1997
17. 17. Coukell AJ, Spencer CM. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 53:520-538, 1997 [review]
18. 18. Muggia FM, Hainsworth JD, Jeffers S, et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987-993, 1997
19. 19. Sledge GJ, Robert N, Sparano JA, et al.: Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 22:105-108, 1995 [review]
20. 20. Buzdar AU, Holmes FA, Hortobagyi GN. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience. Semin Oncol 22:101-104, 1995 [review]
21. 21. Holmes FA, Madden T, Newman RA, et al.: Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14:2713-2721, 1996
22. 22. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334:1-6, 1996